brain cancer News
-
JPM Biotech Showcase Presentation
Reglagene's CEO Richard Austin presented at JPM #BiotechShowcase this afternoon. This was a very exciting presentation as Richard announced the selection of Reglagene's Clinical Candidate for brain ...
-
2nd PhD student appointed to the Toxicity Atlas project
We are very happy to welcome Ghislaine Deutsch as the second PhD student working on the Toxicity Atlas! In the Toxicity Atlas project, Medstoner Silvia Scoarta, VUmc professor Bart Westerman, and their team are researching better ways to treat brain cancer. Quite the task! Ghislaine’s expertise in biology and bio-informatics will make a great contribution to the project by, among other ...
-
Curasight expands its strategy and strengthen its position as a theranostic company
Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company. With reference to the ...
By Curasight
-
Pesticides linked to childhood brain cancers
There is much grey matter surrounding causes of brain cancer in children, but there is increasing evidence indicating that a culprit may be pre-birth pesticide exposure. In a new study released by the National Institute of Health Sciences, herbicide use appeared to cause an elevated risk for cancer. The study found that children living in homes where their parents use pesticides are twice as ...
-
Lauren Sciences LLC awarded second grant for LAUR-401 from Voices Against Brain Cancer
New York, New York, February 7, 2017 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart™ Nanomedicines for brain diseases, today announced the award of its second grant from Voices Against Brain Cancer (VABC). VABC grant will support Lauren Sciences continued development of LAUR-401, its novel V-Smart™ Nanomedicine for Glioblastoma ...
-
Lauren Sciences awarded grant by Voices Against Brain Cancer to develop V-Smart Nanomedicine for GBM
New York, New York, June 30, 2015 -- Lauren Sciences LLC, the private New York biotechnology company developing breakthrough V-Smart™ Nanomedicines for brain diseases, announced today the award of a grant by Voices Against Brain Cancer (VABC). VABC funding will support the development of a V-Smart™ for glioblastoma multiforme (GBM). The future success of V-Smart™ for GBM should ...
-
Aurora BioPharma Attends the 2017 J.P. Morgan Healthcare Conference
Aurora BioPharma, Inc. attends the 35th Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2017 at the Westin St. Francis Hotel in San Francisco, California. About Aurora BioPharma Aurora BioPharma is a biotechnology company, revolutionizing the way we will treat cancer in the future. After 50 years of surgery, radiation and chemotherapy, cancer rates are still expected to ...
-
Made in Quebec: Illuminating hidden brain cancer cells
It’s a scene that plays out daily in operating rooms around the world: a surgeon removes a malignant brain tumour. But rather than registering the satisfaction of having saved a patient’s life, hanging in the air is an all-too-real statistic; in 99.5% of these operations, unseen cancer cells remain. That hidden cancer will eventually grow and spread, and the operation will have become ...
-
xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting
Today, xCures announced that they will present two posters at the 27th Annual Meeting of the Society for Neuro-Oncology, from the 16th to the 20th of November 2022, in Tampa Bay, Florida. The Society for Neuro-Oncology is a multidisciplinary society of healthcare professionals dedicated to promoting advances in neuro-oncology through research and education. Their annual meeting features research ...
By xCures
-
Aurora BioPharma to Attend Pioneers 2017 at the Mandarin Oriental Hotel in New York
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will attend Pioneers 2017 presented by Joseph Gunnar & Co., LLC taking place Tuesday May 2nd at the Mandarin Oriental Hotel in New York. About Joseph Gunnar & Co., LLC Joseph Gunnar & Co., LLC was founded in 1997 ...
-
Vinyl Chloride and Potential Exposure Concerns Discussed in New Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses the industrial chemical known as vinyl chloride and potential exposure concerns. “Vinyl chloride is an important industrial chemical that is produced in large quantities as a chemical intermediate for manufacturing other products, such ...
-
Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart Platform, and selected as a Featured Company, in new report by MCD Group
New York, N.Y., June 18, 2013 -- Lauren Sciences, a privately-held biotechnology company furthering development of its novel V-Smart™ nanovesicle platform technology, announced today that it was independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in a new report by MCD Group. The report, "Early Stage Drug ...
-
Hanne Damgaard Jensen joins Curasight A/S as Chief Development Officer (CDO)
Curasight A/S (“Curasight” or the “Company”) appoints Hanne Damgaard Jensen as new Chief Development Officer. Curasight intends to expand and accelerate its clinical programs and is strengthening the organisation with Hanne Damgaard Jensen who will take on the position as Chief Development Officer (CDO) from 1 January 2022. Hanne will be responsible for all Drug ...
By Curasight
-
Aurora BioPharma to Attend the New York BIO 2017 Annual Conference at 10 on the Park @ Time Warner Center in Columbus Circle
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will attend the New York BIO 2017 Annual Conference taking place May 10-11, at 10 on the Park @ Time Warner Center in Columbus Circle. The event attracts a global audience including attendees from Europe and Asia. The ...
-
Aurora BioPharma to Attend 29th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, CA
Aurora BioPharma, a clinical stage biotechnology company, developing genetically programmed CAR T Cell Therapy to treat Liquid and Solid tumors, will attend the 29th Annual ROTH Conference on March 13, 2017 at the Ritz Carlton, Laguna Niguel, in Dana Point, CA. Robert Brooks, President and CEO, will be available for one-on-one meetings. About 29th Annual ROTH Conference The ROTH conference is ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
Aurora BioPharma To Join In On A Presentation And Discussion On The GBM AGILE Trial At The Ritz-Carlton, Pentagon City
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will join in on a presentation and discussion of the GBM AGILE (Adaptive, Global, Innovative, Learning Environment) trial. The meeting is being held at the Ritz Carlton, at Fashion Centre at Pentagon City, April 11th. About ...
-
TVAX Biomedical Receives Fast Track Designation from the FDA
TVAX Biomedical today announced receipt of Fast Track Designation from the US Food and Drug Administration (FDA) for the use of its vaccineenhanced adoptive T cell therapy (VACT) for treatment of glioblastoma multiforme. “We are very pleased to receive Fast Track Designation by the FDA for glioblastoma multiforme (GBM),” stated Dr. Wayne Carter, Chief Executive Officer. Glioblastoma ...
-
Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Jubilant Therapeutics Inc. a clinical stage precision therapeutics Company advancing small molecule therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced data to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The data report on the pharmacokinetic and in vitro and in vivo anti-cancer properties of JBI-2174, the ...
-
Aesther Healthcare (AEHA) Announces $75M Share Purchase Agreement for Ocean Biomedical Deal
Aesther Healthcare (NASDAQ:AEHA) announced this morning that it has inked a common stock purchase agreement with White Lion Capital that will provide up to $75 million to its combination target Ocean Biomedical. Following close, Ocean may direct White Lion to purchase shares in the company worth up to $2 million or 67% of the five-day average daily trading volume. White Lion previously signed an ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you